Replies to post #81511 on NanoViricides Inc (NNVC)

[BonelessCat]

Facts in evidence of Pharma deals with drugs with less than Phase 3 completion:

Gliknik and Pfizer for GL-2045, $25 million upfront plus benchmark payments. Drug was IND-enabled and not yet in trials.
http://www.prnewswire.com/news-releases/gliknik-enters-into-licensing-agreement-with-pfizer-for-drug-candidate-targeting-autoimmune-diseases-225786531.html

Merrimack Pharmaceuticals and sanofi-aventis for MM-121, $60 million up front plus $460 million in benchmarks, Drug was in Phase 1.
http://www.wilmerhale.com/pages/publicationsandnewsdetail.aspx?NewsPubId=100552

Merck and Cardiome Pharma for Vernakalant, upfront $60M and Up to $300M in Milestones, Merck initiated Phase 3 trials.
http://www.fiercebiotech.com/press-releases/merck-and-cardiome-pharma-sign-license-agreement-vernakalant-investigational-drug-tre

Successful completion of Phase 2 becomes a slam-dunk for a license agreement for $300 million+ just looking at these 3 examples.

That would be assuming facts not in evidence…the fact is NNVC does not have enough money to complete drug trials….and nobody knows if that money will be made available via a partnership….or dilution to shareholders….presuming this doubtful drug with a pretentious name even passes said trials……lot of assumption here……stock price says otherwise.